Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Although treatment with immune checkpoint inhibitors (ICIs) is associated with better survival in many cancer settings, these therapeutics can induce immune-related adverse events (IrAEs).1 ,2 REISAMICi is a French, prospective, multicentre, academic registry sponsored by the Gustave Roussy Institute cancer centre. The objective is to better detect, document and manage IrAEs.
Connective tissue diseases (CTD) have not previously been reported in patients treated with anti-PD1/PDL-1 agents. The REISAMIC registry was screened for reports of CTD.
Of the 447 patients supervised in the REISAMIC registry, three have developed CTD: two cases of Sjögren's syndrome and one case of cryoglobulinemic vasculitis as a complication of suspected Sjögren's syndrome (table 1). A case of ANA+ myositis registered in REISAMIC by another investigating centre …
Contributors OL, the corresponding author, states that all the authors listed have contributed to the work.
Funding LA: research funding: Novartis, Pfizer.
Competing interests Honoraria: SC for Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme and Roche. LA for Novartis, Pfizer, BMS, Sanofi and Ipsen. OL for Merck Sharp Dohme and Genzyme.
Ethics approval Gustave Roussy ethical committee.
Provenance and peer review Not commissioned; externally peer reviewed.
↵i Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie.